Overview:

Short strands of amino acid monomers joined by peptide (amide) bonds are called peptides. Peptide-based Gastrointestinal Therapeutics (GIT) are drugs used in different therapies for GIT conditions such as long-term constipation, tight bowel syndrome, and irritable bowel syndrome. Recently, several peptide therapies such as Linaclotide, Teduglutide and Trulance have obtained approval for the therapy of the GIT condition.

Get Sample Report with Latest Covid19 Analysis @ https://www.coherentmarketinsights.com/insight/request-sample/2028

The guanylate cyclase-C agonist presented for the treatment of chronic idiopathic constipation in the adult population is known as Trulance. The 14 amino acid peptide which functions as an agonist of guanylate cyclase C receptors in the intestinal region is known as Linaclotide. It is a partially imbibed agonist of intestinal guanylate cyclase C receptors and is used in the treatment of intractable constipation and irritable bowel syndrome. Teduglutide is a recently developed recombinant analog for glucagon-like peptide (GLP)-2, an intrinsically stimulating peptide, which transpires especially for the lower gastrointestinal region.

Market dynamics:

The routine approval and commercialization of novel peptide-based gastrointestinal disorder therapeutics in major regional markets had anticipated the growth of the global peptide-based gastrointestinal disorder therapeutics market in the anticipated duration.

For example, in 2012 the United States Food and Drug Administration approved a drug known as Linzess (linaclotide) created in collaboration with Forest Laboratories, Inc. and Ironwood Pharmaceuticals, Inc. Linzess (linaclotide) is a guanylate cyclase-C agonist used in chronic idiopathic constipation (CIC) and treatment of irritable bowel syndrome with constipation (IBS-C).

In 2016, Ironwood Pharmaceuticals, Inc.’s collaboration with Astellas Pharma Inc. obtained commercial clearance from the Japanese Ministry of Health, Labor and Welfare for Linzess (linaclotide), and in 2017, Astellas Pharma Inc. launched Linzess (linaclotide) in Japan.

Request a PDF brochure with the latest insights here @ https://www.coherentmarketinsights.com/insight/request-pdf/2028

Likewise, the growing majority of gastrointestinal ailments had anticipated the growing need for peptide-based drugs that will drive the development of the global peptide-based gastrointestinal disorder therapeutic treatments market. For example, according to the report published in 2016 by the International Foundation for Functional Gastrointestinal Disorders, the most common functional gastrointestinal (GI) disorder in the world is irritable bowel syndrome (IBS), which acquires nearly 10% to 15% of the population.

Regional analysis:

The North America regional Peptide-based Gastrointestinal Disorder Therapeutics market had anticipated significant development in the predicted duration, owing to the existence of giant corporations and adoption of other methods such as partnerships and fusions by them for new peptide-based therapies.

The Asia-Pacific regional market was expected to show a substantial increase in the expected duration, due to increasing acquisitions made by regional companies to obtain approval for new peptide therapies. For example, in 2014, a Japanese pharmaceutical company Astellas Pharma Inc. funded Ironwood Pharmaceuticals, Inc. with an estimated US$15 million, to begin Stage III clinical trials for Linzess (linaclotide) in Japan. In 2016, he obtained permission from the Japanese Ministry of Health, Labor and Welfare.

Key players:

Major companies working in the global peptide-based gastrointestinal disorder therapeutics market contain Allergan plc., Astellas Pharma Inc., Cipher Pharmaceuticals Inc., Ironwood Pharmaceuticals, Inc., NPS Pharmaceuticals, Inc. and Synergy Pharmaceuticals Inc.

Taxonomy:

The Global Peptide-Based Gastrointestinal Disorder Therapeutics Market is divided based on drugs, application, route of administration, distribution channel, and geography.

By medication:

  • Linaclotide

  • Plecanatide (Trulance)

  • Teduglutide

Per application:

  • Chronic constipation

  • irritable bowel syndrome

  • Short bowel syndrome

  • Others

By administration:

By distribution channel:

  • Hospital pharmacies

  • Online pharmacies

  • Retail pharmacies

By geography:

  • North America

  • Africa

  • Asia Pacific

  • Europe

  • Latin America

  • Middle East

Buy this full business report with a fixed discount of 2000 USD @ https://www.coherentmarketinsights.com/promo/buynow/2028

Reasons to buy this report

Current and future prospects of the Peptide-based Gastrointestinal Disorder Therapeutics Market in both developed and emerging markets
• The segment that is expected to dominate the market as well as the segment that holds the highest CAGR during the forecast period.
• Regions/countries expected to experience the fastest growth rates during the forecast period
• The latest developments, market shares and strategies employed by major market players

Contents

Chapter 1 Industry overview
1.1 Definition
1.2 Assumptions
1.3 Scope of research
1.4 Market Analysis by Regions
1.5 Peptide-based Gastrointestinal Disorder Therapeutics Market Size Analysis from 2021 to 2028
11.6 COVID-19 Outbreak: Impact on Peptide Gastrointestinal Disorder Therapeutics Industry

Chapter 2 Global Peptide-Based Gastrointestinal Disorder Therapies Competition by Types, Applications, and Top Regions & Countries
2.1 Global Peptide-Based Gastrointestinal Disorder Therapeutics (Volume & Value) by Type
2.3 Global Peptide-Based Gastrointestinal Disorder Therapeutics (Volume and Value) by Regions

chapter 3 Generation market analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis

Chapter 4 Global Peptide Gastrointestinal Disorder Therapeutics Sales, Consumption, Export, Import by Regions (2016-2021)
Chapter 5 North America Peptide Gastrointestinal Disorder Therapeutics Market Analysis
Chapter 6 Market Analysis of Peptide Gastrointestinal Disorder Therapeutics in East Asia
Chapter 7 Market Analysis of Peptide Gastrointestinal Disorder Therapeutics in Europe
Chapter 8 Market Analysis of Peptide-Based Gastrointestinal Disorder Therapeutics in South Asia
Chapter 9 Market Analysis of Peptide Gastrointestinal Disorder Therapeutics in Southeast Asia
Chapter 10 Market Analysis of Peptide-Based Gastrointestinal Disorder Therapeutics in the Middle East
Chapter 11 Market Analysis of Peptide-Based Gastrointestinal Disorder Therapeutics in Africa
Chapter 12 Market Analysis of Peptide Gastrointestinal Disorder Therapeutics in Oceania
Chapter 13 Market Analysis of Peptide-Based Gastrointestinal Disorder Therapeutics in South America
Chapter 14 Company Profiles and Key Figures in the Field of Peptide Gastrointestinal Disorder Therapies
Chapter 15 Global Peptide-Based Gastrointestinal Disorder Therapeutics Market Forecast (2021-2027)
Chapter 16 conclusion
Research Methodology

About Us:

Coherent Market Insights is a global market intelligence and advisory organization that provides syndicated research reports, custom research reports and advisory services. We’re known for our actionable insights and genuine reports in a variety of fields, including aerospace and defense, agriculture, food and beverage, automotive, chemicals and materials, and virtually any field and an exhaustive list of subdomains under the sun. We create value for our clients through our highly reliable and accurate reports. We are also committed to playing a leading role in providing insight in various post-COVID-19 sectors and to continuing to deliver measurable and sustainable results to our clients.

Contact:

Consistent market information
1001 4th Ave, #3200 Seattle, WA 98154, USA
Email: [email protected]
United States of America: +1-206-701-6702
UK: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

About The Author

Related Posts